CVRX INC (CVRX) Stock Price & Overview
NASDAQ:CVRX • US1266381052
Current stock price
The current stock price of CVRX is 7.53 USD. Today CVRX is up by 1.21%. In the past month the price increased by 32.34%. In the past year, price decreased by -34.18%.
CVRX Key Statistics
- Market Cap
- 198.114M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.05
- Dividend Yield
- N/A
CVRX Stock Performance
CVRX Stock Chart
CVRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CVRX. When comparing the yearly performance of all stocks, CVRX is a bad performer in the overall market: 84.72% of all stocks are doing better.
CVRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVRX. CVRX may be in some trouble as it scores bad on both profitability and health.
CVRX Earnings
On February 12, 2026 CVRX reported an EPS of -0.46 and a revenue of 16.02M. The company missed EPS expectations (-2.76% surprise) and missed revenue expectations (-0.72% surprise).
CVRX Forecast & Estimates
13 analysts have analysed CVRX and the average price target is 12.44 USD. This implies a price increase of 65.26% is expected in the next year compared to the current price of 7.53.
For the next year, analysts expect an EPS growth of 2.19% and a revenue growth 15.14% for CVRX
CVRX Groups
Sector & Classification
CVRX Financial Highlights
Over the last trailing twelve months CVRX reported a non-GAAP Earnings per Share(EPS) of -2.05. The EPS increased by 23.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.87% | ||
| ROE | -135.56% | ||
| Debt/Equity | 1.26 |
CVRX Ownership
CVRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.81 | 187.913B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.2 | 170.203B | ||
| SYK | STRYKER CORP | 22.27 | 129.047B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.77 | 101.721B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.52 | 49.099B | ||
| IDXX | IDEXX LABORATORIES INC | 38.71 | 45.48B | ||
| BDX | BECTON DICKINSON AND CO | 11.69 | 45.453B | ||
| RMD | RESMED INC | 18.8 | 33.857B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.69 | 32.053B | ||
| DXCM | DEXCOM INC | 25.27 | 25.116B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.99 | 18.115B | ||
| HOLX | HOLOGIC INC | 15.3 | 16.79B | ||
| PODD | INSULET CORP | 34 | 16.619B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVRX
Company Profile
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 223 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
Company Info
IPO: 2021-06-30
CVRX INC
9201 West Broadway Avenue, Suite 650
Minneapolis MINNESOTA US
CEO: Nadim Yared
Employees: 206
Phone: 17634162850
CVRX INC / CVRX FAQ
Can you describe the business of CVRX INC?
CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 223 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The firm's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
What is the current price of CVRX stock?
The current stock price of CVRX is 7.53 USD. The price increased by 1.21% in the last trading session.
What is the dividend status of CVRX INC?
CVRX does not pay a dividend.
How is the ChartMill rating for CVRX INC?
CVRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about CVRX INC (CVRX) stock?
13 analysts have analysed CVRX and the average price target is 12.44 USD. This implies a price increase of 65.26% is expected in the next year compared to the current price of 7.53.
Is CVRX INC (CVRX) expected to grow?
The Revenue of CVRX INC (CVRX) is expected to grow by 15.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does CVRX INC have?
CVRX INC (CVRX) currently has 206 employees.